Targeted Sequencing of HER2-Positive Breast Cancer Mutations Revealed a Potential Association between PIK3CA and Trastuzumab Resistance.

ABSTRACT:

Background

Different molecular subtypes, including HER2-positive, have been identified in breast cancer. The overexpression of HER2 triggers downstream signaling pathways such as the PI3K/AKT/mTOR pathway. Until recently, trastuzumab has been used as a single HER2-targeted therapy in Egypt. However, resistance to trastuzumab has been reported. Previous studies have demonstrated the genetic variants that affect the trastuzumab response. However in Egypt, few studies investigated molecular biomarkers such as p53 that might affect the trastuzumab response. Therefore, we aimed to extend the genetics workup of Her2 + BC to include important oncogenes and other vital cancer pathways.

Methods

Formalin-fixed paraffin-embedded samples were collected from 24 HER2+ BC Egyptian patients

SUBMITTER: Mekhamer AM 

PROVIDER: S-EPMC11996105 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature